Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma

Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a cytotoxic chemotherapy-resistant tumor and most HCCs arise in a background of liver cirrhosis of various causes. Although the IMBrave150 trial showed remarkable advancements in the treatment of unresectable HCC with atezolizumab plus bevacizumab (AteBeva), therape...

Full description

Bibliographic Details
Main Authors: Ahlim Lee, Jaejun Lee, Hyun Yang, Soo-Yoon Sung, Chang Ho Jeon, Su Ho Kim, Moon Hyung Choi, Young Joon Lee, Ho Jong Chun, Si Hyun Bae
Format: Article
Language:English
Published: Korean Liver Cancer Association 2022-03-01
Series:Journal of Liver Cancer
Subjects:
hepatocellular carcinoma
atezolizumab
bevacizumab
multidisciplinary treatment
case report
Online Access:http://e-jlc.org/upload/pdf/jlc-2022-03-04.pdf

Internet

http://e-jlc.org/upload/pdf/jlc-2022-03-04.pdf

Similar Items